Biointerface

Interface Biosciences is a biotechnology company focused on developing next-generation immunotherapies by leveraging the co-evolved relationship between humans and their commensal microbes. The company utilizes a proprietary AI-guided platform that combines precision culturomics, targeted metabolomics, and molecular engineering to mine natural product libraries for safe and effective therapeutic scaffolds. Their primary focus is on multi-targeted therapies for complex diseases such as autoimmune disorders and cancer, where traditional single-mechanism drugs often fall short. By identifying and optimizing chemical scaffolds produced by commensals, Interface Biosciences aims to generate a pipeline of high-potency, low-toxicity medicines at an accelerated rate.